<table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl2" position="float"><object-id pub-id-type="doi">10.7554/eLife.16644.007</object-id><label>Table 2.</label><caption><p>Identified events of within-patient acquired resistance.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16644.007">http://dx.doi.org/10.7554/eLife.16644.007</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th><p>Isolate ID</p> </th><th><p>HIV</p> </th><th><p>Treatment history</p> </th><th><p>Mutation</p> </th><th><p>Acquired resistance</p> </th></tr></thead><tbody><tr><td><p>107</p> </td><td><p>-</p> </td><td><p>follow-up (ETH* treated)</p> </td><td><p><italic>ethA</italic> L225fs</p> </td><td><p>ETH</p> </td></tr><tr><td><p>108</p> </td><td><p>-</p> </td><td><p>follow-up (ETH and FLQ treated)</p> </td><td><p><italic>ethA</italic> S208P</p> </td><td><p>ETH</p> </td></tr><tr><td><p>516</p> </td><td><p>-</p> </td><td><p>follow-up (unknown treatment)</p> </td><td><p><italic>pncA</italic> D129G</p> </td><td><p>PZA</p> </td></tr><tr><td><p>1757</p> </td><td><p>-</p> </td><td><p>follow-up (ETH and FLQ treated)</p> </td><td><p><italic>ethA</italic> H22P</p> </td><td><p>ETH</p> </td></tr><tr><td><p>2098</p> </td><td><p>-</p> </td><td><p>follow-up (ETH and FLQ treated)</p> </td><td><p><italic>ethA</italic> F302S + <italic>gyrB</italic> D461V</p> </td><td><p>ETH + FLQ</p> </td></tr><tr><td><p>2485</p> </td><td><p>-</p> </td><td><p>follow-up (unknown treatment)</p> </td><td><p><italic>ethA</italic> G437fs</p> </td><td><p>ETH</p> </td></tr><tr><td><p>POGU</p> </td><td><p>-</p> </td><td><p>follow-up (ETH and FLQ treated)</p> </td><td><p><italic>ethA</italic> R259fs + <italic>gyrB</italic> R292G</p> </td><td><p>ETH + FLQ</p> </td></tr><tr><td><p>110</p> </td><td><p>+</p> </td><td><p>follow-up (ETH and FLQ treated)</p> </td><td><p><italic>gyrB</italic> R446S</p> </td><td><p>FLQ</p> </td></tr><tr><td><p>257</p> </td><td><p>+</p> </td><td><p>follow-up (ETH and FLQ treated)</p> </td><td><p><italic>inhA</italic> -15 C&gt;T</p> </td><td><p>ETH</p> </td></tr><tr><td><p>1298</p> </td><td><p>+</p> </td><td><p>follow-up (ETH and FLQ treated)</p> </td><td><p><italic>gyrA</italic> D94N</p> </td><td><p>FLQ</p> </td></tr><tr><td><p>2569</p> </td><td><p>+</p> </td><td><p>follow-up (ETH treated)</p> </td><td><p><italic>ethA</italic> S251fs</p> </td><td><p>ETH</p> </td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>*Patient received the ETH analogue prothionamide</p></fn></table-wrap-foot></table-wrap>